Son Dönem Böbrek Yetmezliği Olan Diyabetik Hastada Repaglinid Bağlı Hipoglisemi Olgusu

Bülent Huddam, Emine Koca, Dilek Gibyeli Genek, Okşan Uyar Gazezoğlu, Volkan Karakuş

Özet


Özet

Diyabetes mellitus tüm dünyada giderek artan sıklıkta görülmektedir ve Son dönem böbrek yetmezliği (SDBY)’nin en sık sebebidir.  Kronik böbrek yetmezliği durumunda karbonhidrat ve insülin metabolizmasında oluşan değişiklikler ve diyabet için kullanılan ilaçların renal klirensinin değişmesi kan şeker regülasyonun da zorluklara neden olduğundan dolayı SDBY hastalarında diyabet tedavisi özellik arz etmektedir. Bu yazıda 80 yaşında son dönem böbrek yetmezliği olan bir tip 2 diyabetes mellitus vakasında meglitinid kullanımına bağlı gelişen nadir bir durum olan hipoglisemiyi irdelemek amacı ile sunulmuştur.

Anahtar Kelimeler: Böbrek yetmezliği, Hipoglisemi, Repaglinid

Abstract

Prevalence of the diabetes mellitus (DM) is increasing in whole world and it is the most common reason of end stage renal disease. At chronic renal failure condition alteration of carbonhydrate and insulin metabolism and alteration of the renal clearance of the drugs using for diabetes cause difficulties of blood glucose regulation for this reason diabetes treatment is very important for end stage kidney disease patients. In this case presented for examine rare condition hypoglycemia linked using of meglitinide at patient who at 80 years old have type 2 DM and end stage kidney disease.  

Keywords: Hypoglycemia, Renal failure, Repaglinid


Tam Metin:

PDF

Referanslar


Kaynaklar

Kovesdy CP, Sharma K, Kalantar-Zadeh K. Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis. 2008;52(4):766-77.

Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17(4 Suppl 2):86-9.

Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol. 2010;5(9):1595-601.

Richard JW 3rd, Raskin P. Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes. 2011;4:29-37.

Hu S. Interaction of nateglinide with K (ATP) channel in beta-cells underlies its unique insulinotropic action. Eur J Pharmacol. 2002;442(1–2):163–71.

Hatorp V, Huang WC, Strange P. Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Clin Ther. 1999;21(4):702–10.

Campbell IW. Nateglinide— current and future role in the treatment of patients with type 2 diabetes mellitus.Int J Clin Pract. 2005;59(10):1218–28.

Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract. 2003;59(1):43–9.

Chen M, Hu C, Jia W. Pharmacogenomics of glinides. Pharmacogenomics. 2015;16(1):45-60.

;442(1–2):163–71.

Hatorp V, Huang WC, Strange P. Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Clin Ther. 1999 Apr;21(4):702–10.

Campbell IW. Nateglinide— current and future role in the treatment of patients with type 2 diabetes mellitus.Int J Clin Pract. 2005 Oct;59(10):1218–28.

Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract. 2003 Jan;59(1):43–9.

Chen M, Hu C, Jia W. Pharmacogenomics of glinides. Pharmacogenomics. 2015

Jan;16(1):45-60.


Refback'ler

  • Şu halde refbacks yoktur.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.